Position of fixed‐dose combinations containing an AT₁‐receptor blocker and a thiazide diuretic

References

• Brunner H. R., Menard J., Waeber B., Burnier M., Biollaz J., Nussberger J., et al. Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3–11
   PubMed Web of Science ®Google Scholar
• Epstein M., Bakris G. Newer approaches to antihypertensive therapy. Use of fixed‐dose combination therapy. Arch Intern Med 1996; 156: 1969–1978
   PubMed Web of Science ®Google Scholar
• Law M. R., Moris J. K., Jordan R. E. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomized trials. BMJ 2003; 326: 1–8
   Google Scholar
• Brunner H. R., Waeber B., Nussberger J. Renin secretion responsiveness: Understanding the efficacy of renin–angiotensin inhibition. Kidney Int 1988; 26: S80–S85
   Google Scholar
• Brunner H. R., Laragh J. H., Baer L., Newton M. A., Goodwin F. T., Krakoff L. R., et al. Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441–449
   PubMed Web of Science ®Google Scholar
• Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin‐sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–1104
   PubMed Web of Science ®Google Scholar
• Weiss D., Sorescu D., Taylor W. R. Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87: 25C–32C
   PubMed Web of Science ®Google Scholar
• Dzau V. J. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047–1052
   PubMed Web of Science ®Google Scholar
• Ruiz‐Ortega M., Lorenzo O., Suzuki Y., Ruperez M., Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321–329
   PubMed Web of Science ®Google Scholar
• Touyz R. M. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Current Hypertens Rep 2003; 5: 155–164
   PubMed Web of Science ®Google Scholar
• Li D., Saldeen T., Romeo F., Mehta J. L. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: The potential role of transcription factor NF‐kappaB. Circulation 2000; 102: 1970–1976
   PubMed Web of Science ®Google Scholar
• Nickenig G., Bohm M. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. Eur J Med Res 1997; 2: 285–289
   PubMedGoogle Scholar
• Diet F., Pratt R. E., Berry G. J., Momose N., Gibbons G. H., Dzau V. J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756–2767
   PubMed Web of Science ®Google Scholar
• Ihara M., Urata H., Kinoshita A., Suzumiya J., Sasaguri M., Kikuchi M., et al. Increased chymase‐dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399–1405
   PubMed Web of Science ®Google Scholar
• Legedz L., Randon J., Sessa C., Baguet J., Feugier P., Cerutti C., et al. Cathepsin G is associated with atheroma formation in human carotid artery. J Hypertens 2004; 22: 157–166
   Google Scholar
• Lee R. T., Schoen F. J., Loree H. M., Lark M. W., Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arteriosclerosis Thromb Vasc Biol 1996; 16: 1070–1073
   PubMed Web of Science ®Google Scholar
• Berry C., Hamilton C. A., Brosnan M. J., Magill F. G., Berg G. A., McMurray J. J., et al. Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101: 2206–2212
   PubMed Web of Science ®Google Scholar
• Baykal Y., Yilmaz M. I., Celik T., Gok F., Rehber H., Akay C., Kocar I. H. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens 2003; 21: 1207–1211
   PubMed Web of Science ®Google Scholar
• Rahman S. T., Lauten W. B., Khan Q. A., Navalkar S., Parthasarathy S., Khan B. V. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin–angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002; 89: 686–690
   PubMed Web of Science ®Google Scholar
• Germano G., Sanguignib V., Pignatellia P., Cacceseb D., Lentia L., Ragazzoa M., et al. Enhanced platelet release of superoxide anion in systemic hypertension: Role of AT1 receptors. J Hypertens 2004; 22: 1151–1156
   PubMed Web of Science ®Google Scholar
• Navalkar S., Parthasarathy S., Santanam N., Khan B. V. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440–444
   PubMed Web of Science ®Google Scholar
• Khan B. V., Navalkar S., Khan Q. A., Rahman S. T., Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001; 38: 1662–1667
   PubMed Web of Science ®Google Scholar
• Hayek T., Aviram M., Heinrich R., Sakhnini E., Keidar S. Losartan inhibits cellular uptake of oxidized LDL by monocyte‐macrophages from hypercholesterolemic patients. Biochem Biophys Res Commun 2000; 273: 417–420
   PubMed Web of Science ®Google Scholar
• Lauten W. B., Khan Q. A., Rajagopalan S., Lerakis S., Rahman S. T., Parthasarathy S., Khan B. V. Usefulness of quinapril and irbesartan to improve the anti‐inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol 2003; 91: 1116–1119
   PubMed Web of Science ®Google Scholar
• Cipollone F., Fazia M., Iezzi A., Pini B., Cuccurullo C., Zucchelli M., et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2‐dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482–1488
   PubMedGoogle Scholar
• von zur Muhlen B., Kahan T., Hagg A., Millgard J., Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001; 19: 1813–1818
   PubMed Web of Science ®Google Scholar
• Ghiadoni L., Virdis A., Magagna A., Taddei S., Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 501–506
   PubMed Web of Science ®Google Scholar
• Klingbeil A. U., John S., Schneider M. P., Jacobi J., Handrock R., Schmieder R. E. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16: 123–128
   PubMed Web of Science ®Google Scholar
• Prasad A., Halcox J. P., Waclawiw M. A., Quyyumi A. A. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol 2001; 38: 1089–1095
   Google Scholar
• Cheetham C., Collis J., O'Driscoll G., Stanton K., Taylor R., Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non‐insulin‐dependent diabetes. J Am Coll Cardiol 2000; 36: 1461–1466
   PubMed Web of Science ®Google Scholar
• Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diab Complic 2000; 14: 154–174
   Google Scholar
• Haffner S. M. Pre‐diabetes, insulin resistance, inflammation and CVD risk. Diab Res Clin Pract 2003; 61(Suppl 1)S9–S18
   PubMedGoogle Scholar
• Sola S., Mir M. Q., Cheema F. A., Khan‐Merchant N., Menon R. G., Parthasarathy S., et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343–348
   PubMed Web of Science ®Google Scholar
• Mahmud A., Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: Beyond blood pressure reduction. Am J Hypertens 2002; 15: 1092–1095
   PubMedGoogle Scholar
• Schiffrin E. L., Park J. B., Intengan H. D., Touyz R. M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653–1659
   PubMed Web of Science ®Google Scholar
• Vaughan D. E. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001; 87: 18C–24C
   Google Scholar
• Ridker P. M., Gaboury C. L., Conlin P. R., Seely E. W., Williams G. H., Vaughan D. E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin–angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969–1973
   PubMed Web of Science ®Google Scholar
• Erdem Y., Usalan C., Haznedaroglu I. C., Altun B., Arici M., Yasavul U., et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12: 1071–1076
   PubMed Web of Science ®Google Scholar
• Makris T. K., Stavroulakis G. A., Krespi P. G., Hatzizacharias A. N., Triposkiadis F. K., Tsoukala C. G., et al. Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783–788
   PubMed Web of Science ®Google Scholar
• Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566
   PubMed Web of Science ®Google Scholar
• Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54
   PubMed Web of Science ®Google Scholar
• Schuijt M. P., Danser A. H. Cardiac angiotensin II: An intracrine hormone?. Am J Hypertens 2002; 15: 1109–1116
   PubMed Web of Science ®Google Scholar
• Urata H., Nishimura H., Ganten D., Arakawa K. Angiotensin‐converting enzyme‐independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press 1996; 5(Suppl 2)22–28
   Google Scholar
• Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–1176
   PubMed Web of Science ®Google Scholar
• Gaudio C., Ferri F. M., Giovannini M., Pannarale G., Puddu P. E., Vittore A., et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003; 42: 622–628
   PubMed Web of Science ®Google Scholar
• Klingbeil A. U., Schneider M., Martus P., Messerli F. H., Schmieder R. E. A meta‐analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–46
   PubMed Web of Science ®Google Scholar
• Cuocolo A., Storto G., Izzo R., Iovino G. L., Damiano M., Bertocchi F., et al. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: Comparison with enalapril. J Hypertens 1999; 17: 1759–1766
   PubMed Web of Science ®Google Scholar
• Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003
   PubMed Web of Science ®Google Scholar
• Clarkson P. B., Naas A. A., McMahon A., MacLeod C., Struthers A. D., MacDonald T. M. QT dispersion in essential hypertension. QJM 1995; 88: 327–332
   PubMed Web of Science ®Google Scholar
• Davey P. P., Bateman J., Mulligan I. P., Forfar C., Barlow C., Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: Relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994; 71: 268–273
   Google Scholar
• Lim P. O., Nys M., Naas A. A., Struthers A. D., Osbakken M., MacDonald T. M. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999; 33: 713–718
   PubMed Web of Science ®Google Scholar
• Kawabata M., Takabatake T., Ohta H., Nakamura S., Hara H., Ohta K., et al. Effects of an angiotensin II receptor antagonist, TCV‐116, on renal haemodynamics in essential hypertension. Blood Press 1994; 5(Suppl)117–121
   Google Scholar
• Navar L. G., Harrison‐Bernard L. M., Imig J. D., Cervenka L., Mitchell K. D. Renal responses to AT1 receptor blockade. Am J Hypertens 2000; 13(Suppl)45S–54S
   Google Scholar
• Taal M. W., Brenner B. M. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803–1817
   PubMed Web of Science ®Google Scholar
• Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Brenner B. M., Cooper M. E., de Zeeuw D., Keane W. F., Mitch W. E., Parving H. H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869
   PubMed Web of Science ®Google Scholar
• Parving H. H., Lehnert H., Brochner‐Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878
   PubMed Web of Science ®Google Scholar
• Viberti G., Wheeldon N. M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure‐independent effect. Circulation 2002; 106: 672–678
   PubMed Web of Science ®Google Scholar
• Price D. A., Porter L. E., Gordon M., Fisher N. D., De'Oliveira J. M., Laffel L. M., et al. The paradox of the low‐renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382–2391
   PubMed Web of Science ®Google Scholar
• Fliser D., Keller C., Bahrmann P., Franek E., Schreckling H., Bergis K., et al. Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset. J Hypertens 1997; 15: 293–299
   Google Scholar
• Waeber B., Feihl F., Ruilope L. Diabetes and hypertension. Blood Press 2001; 10: 311–321
   PubMed Web of Science ®Google Scholar
• Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double‐blind intervention trial. J Hypertens 2003; 21: 875–886
   PubMed Web of Science ®Google Scholar
• Tedesco M. A., Ratti G., Mennella S., Manzo G., Grieco M., Rainone A. C., et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12: 1130–1134
   PubMed Web of Science ®Google Scholar
• Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–1226
   PubMed Web of Science ®Google Scholar
• Chrysant S. G., Weber M. A., Wang A. C., Hinman D. J. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17: 252–259
   PubMed Web of Science ®Google Scholar
• Kochar M., Guthrie R., Triscari J., Kassler‐Taub K., Reeves R. A. Matrix study of irbesartan with hydrochlorothiazide in mild‐to‐moderate hypertension. Am J Hypertens 1999; 12: 797–805
   PubMed Web of Science ®Google Scholar
• MacKay J. H., Arcuri K. E., Goldberg A. I., Snapinn S. M., Sweet C. S. Losartan and low‐dose hydrochlorothiazide in patients with essential hypertension. A double‐blind, placebo‐controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–285
   PubMed Web of Science ®Google Scholar
• Philipp T., Letzel H., Arens H. J. Dose‐finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11(Suppl 2)67–68
   Google Scholar
• Benz J. R., Black H. R., Graff A., Reed A., Fitzsimmons S., Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double‐blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–866
   PubMed Web of Science ®Google Scholar
• McGill J. B., Reilly P. A. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clin Ther 2001; 23: 833–850
   PubMed Web of Science ®Google Scholar
• Schoenberger J. A. Losartan with hydrochlorothiazide in patients with mild to moderate hypertension. J Hypertens 1995; 13(Suppl 1)S43–S47
   Google Scholar
• Campbell M., Sonkodi S., Soucek M., Wiecek A. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens 2001; 23: 345–355
   PubMed Web of Science ®Google Scholar
• Plouin P. F. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low‐dose hydrochlorothiazide. J Hum Hypertens 1997; 11(Suppl 2)65–66
   Google Scholar
• Hall D., Motoro R., Littlejohn T., Jain A., Feliciano N., Zheng H. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clinical Drug Investigations 1998; 16: 203–210
   PubMed Web of Science ®Google Scholar
• Rosenstock J., Rossi L., Lin C. S., MacNeil D., Osbakken M. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non‐responsive to hydrochlorothiazide alone. J Clin Pharmacol Ther 1998; 23: 433–440
   PubMed Web of Science ®Google Scholar
• Perez‐Stable E., Caralis P. V. Thiazide‐induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J 1983; 106: 245–251
   PubMedGoogle Scholar
• McGill J. B., Reilly P. A. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001; 24: 66–72
   PubMed Web of Science ®Google Scholar
• Wellington K., Faulds D. M. Valsartan/hydrochlorothiazide: A review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62: 1983–2005
   PubMed Web of Science ®Google Scholar
• Melian E. B., Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 2002; 62: 787–816
   PubMed Web of Science ®Google Scholar
• Soffer B. A., Wright J. T, Jr., Pratt J. H., Wiens B., Goldberg A. I., Sweet C. S. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–117
   PubMed Web of Science ®Google Scholar
• Amos A. F., McCarty D. J., Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diab Med 1997; 14(Suppl 5)S1–S85
   PubMedGoogle Scholar
• Reaven G. M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374–381
   PubMed Web of Science ®Google Scholar
• Padwal R., Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care 2004; 247–255
   Google Scholar
• Grassi G., Seravalle G., Dell'Oro R., Trevano F. Q., Bombelli M., Scopelliti F., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 2003; 21: 1761–1769
   PubMed Web of Science ®Google Scholar
• Lindholm L. H., Persson M., Alaupovic P., Carlberg B., Svensson A., Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563–1574
   PubMed Web of Science ®Google Scholar
• Pepine C. J., Handberg E. M., Cooper‐DeHoff R. M., Marks R. G., Kowey P., Messerli F. H., et al. A calcium antagonist vs a non‐calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil‐Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290: 2805–2816
   PubMed Web of Science ®Google Scholar
• Baron A. D., Brechtel‐Hook G., Johnson A., Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993; 21: 129–135
   PubMed Web of Science ®Google Scholar
• Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., et al. Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arteriosclerosis Thromb Vasc Biol 2004; 24: 29–33
   PubMed Web of Science ®Google Scholar
• Douglas J. G., Bakris G. L., Epstein M., Ferdinand K. C., Ferrario C., Flack J. M., et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 525–541
   PubMed Web of Science ®Google Scholar
• Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992
   PubMed Web of Science ®Google Scholar
• Lemogoum D., Seedat Y. K., Mabadeje A. F., Mendis S., Bovet P., Onwubere B., et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub‐Saharan Africa. J Hypertens 2003; 21: 1993–2000
   PubMed Web of Science ®Google Scholar